RareResearch.AI
← Back to atlas

V503I

Category 4 — Stable Fold, Function DisruptedConflictingTransmembrane · predictedEditorial
ValineIsoleucine at position 503 · TM6 (496-516), helical transmembrane · WFS1 (Wolframin)

Val→Ile p503 TM6 AM=0.06 ddg=-0.22 pLDDT=81. ClinVar Conflicting evidence. Atlas mechanism: see structural analysis.

Interactive 3D Structure

Wild-type reference
Wild-type V503 — hydrogen bond to L506
Fullscreen ↗
DynaMut2 mutant · V503I
Mutant I503 — hydrogen bond contact to L484 lost
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

0 lost2 gained10 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondL484L484Preserved
Hydrogen bondL506L506Preserved
Hydrogen bondL507L507Preserved
Polar contactL484L484Preserved
Polar contactC505C505Preserved
Polar contactL506L506Preserved
Polar contactL507L507Preserved
Van der WaalsL484Gained
Van der WaalsL506L506Preserved
HydrophobicL468L468Preserved
HydrophobicL484Gained
HydrophobicF488F488Preserved

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-0.22kcal/mol
Destabilising — mild
AlphaMissense
0.060
LBen
AlphaFold pLDDT
81
model confidence
Schema
Cat 4
Category 4 — Stable Fold, Function Disrupted
ΔΔG confidence: Reduced confidence · Transmembrane
  • transmembrane position; predictor benchmarked on soluble proteins

This variant sits in the transmembrane band. The stability value was computed with a predictor benchmarked on water-soluble proteins. Published benchmarks of ddG predictors on membrane proteins report correlation below 0.4. Treat the magnitude as unreliable and the sign as weak evidence only.

Do not rank this value against a variant from a different region on ΔΔG alone.

Clinical Evidence

ClinVar classificationConflicting classifications of pathogenicity
Review statuscriteria provided, conflicting classifications
Associated conditions(no specific conditions catalogued)
InheritanceConflicting ClinVar classifications.
Population frequency (gnomAD v4)Ultra-rare · AF 0.0063%
cDNA changec.1507G>A
ClinVar accessionVCV000215357
Last evaluated2025/09/20 00:00

Observed at very low frequency in gnomAD.

Classified for1★ unverified submission

ClinVar classifies this variant as Conflicting classifications of pathogenicity for WFS1-related spectrum (unresolved mode) (dominant or recessive); Cataract 41 (autosomal dominant, OMIM 116400); Nonsyndromic hearing loss (DFNA6/14/38) (autosomal dominant, OMIM 600965); WFS1-related diabetes (autosomal dominant); Wolfram syndrome (classic) (autosomal recessive, OMIM 222300); Wolfram-like syndrome (autosomal dominant, OMIM 614296). ClinVar records this under a WFS1-spectrum label that spans both disease families — recessive Wolfram syndrome (biallelic) and the dominant WFS1-related disorders. The label does not resolve which applies, and it is not a severity statement.

  • WFS1-related spectrum (unresolved mode)dominant or recessivesubmitted as: WFS1-Related Spectrum Disorders
  • Cataract 41autosomal dominant · OMIM 116400submitted as: Cataract 41
  • Nonsyndromic hearing loss (DFNA6/14/38)autosomal dominant · OMIM 600965submitted as: Autosomal dominant nonsyndromic hearing loss 6; Autosomal dominant nonsyndromic hearing loss 6
  • WFS1-related diabetesautosomal dominantsubmitted as: Type 2 diabetes mellitus
  • Wolfram syndrome (classic)autosomal recessive · OMIM 222300submitted as: Wolfram syndrome 1; Wolfram syndrome 1
  • Wolfram-like syndromeautosomal dominant · OMIM 614296submitted as: Wolfram-like syndrome
  • Submitters conflict on this classification (1★). Treat the conditions above as submitted, not as documented phenotypes.
  • Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient.
  • Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

Review status: 1★ conflicting classifications. ClinVar "conditions" is the union of all submissions; 0–1★ entries are submitted conditions, not documented phenotypes.

Population frequency
Global (all ancestries)
AF 0.0063% · 102 / 1,611,254 alleles
Homozygotes
0
Highest-frequency population
East Asian · AF 0.036%

Highest in East Asian: AF 0.036% (16 of 44,874 alleles), 5.6x the global figure. The global AF describes the general population, not the at-risk group.

No homozygotes reported in gnomAD v4. For a recessive allele this is expected and is not, on its own, evidence either way.

Ancestry groupAllele freq.AC / ANHom.Carrier est.
East Asian0.036%16 / 44,8740~1 in 1400
Middle Eastern · under-sampled0.016%1 / 6,0620
African / African American0.015%11 / 75,0560~1 in 3410
Admixed American0.012%7 / 60,0260~1 in 4290
South Asian0.0055%5 / 91,0860~1 in 9110
European (non-Finnish)0.0050%59 / 1,180,0140~1 in 10000
Remaining individuals0.0048%3 / 62,4740~1 in 10410

Source: gnomAD r4, retrieved 2026-08-21. Values are allele frequencies. The carrier estimate is derived from the allele frequency (Hardy-Weinberg, ~2·AF) and is an approximation, not a published figure — where a published carrier frequency exists it outranks this column and is cited on the card.

Structural Context

Position analysis: SER502 (2.5 Å), PRO504 (2.5 Å — P504L!), CYS505 (4.3 Å — C505Y!). Same TM6 cluster. The Atlas's neighbor extraction surfaces this variant's contacts and connects them to the broader multi-variant target landscape.

Amino-acid chemistry
conservative branched-aliphatic
Position in the protein
TM6 (496-516)

Druggability Assessment

Cat 4 — see structural prose. AlphaMissense below threshold (AM under-call class) but mechanism is structurally identified. Therapeutic strategy: site-directed at contacts identified above, or wet-lab validation if pLDDT borderline/below 50.

Why this matters

V503I + V503G at same position. TM6 cluster..
Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the V503I PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download V503I PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.

UniProt Domain Annotation

Chain1890 · Wolframin
Transmembrane496516 · Helical